Defense contractor Palantir says a ‘massive cultural shift in the U.S.' has justified 20 years of thankless toil. ‘We were the freak show … and we spent 20 years for this moment'
Palantir's commitment to serving U.S. military and intelligence agencies long made it an outlier in Silicon Valley. For years, CEO Alex Karp recalled on the company's first-quarter earnings call Monday, potential private-sector clients shied away from doing business with the upstart defense contractor and its quixotic chief executive.
But now, as chief technology officer Shyam Sankar noted on the call, companies like AIG, Citi, BP, Hertz, and fellow defense firm L3Harris are touting their gains from using Palantir's flagship Artificial Intelligence Platform, or AIP, to investors. Meanwhile, when it comes to the company's bread and butter, management—along with plenty of investors and Wall Street analysts—believes Palantir is perfectly suited to capitalize on efforts to cut federal spending and streamline government contracting.
'We were the freak show,' Karp said. 'And we spent 20 years for this moment.'
It's not hard to see why he feels vindicated. The company's U.S. revenue in Q1 grew 55% year over year and 13% from last quarter to $628 million. Even after Palantir's highly priced shares fell sharply after the earnings call, the stock is still up roughly 330% in the past year.
Karp, who cofounded the company with Peter Thiel, Stephen Cohen, and Joe Lonsdale in 2004, has become famous for his brazen and philosophical commentary. His quarterly letter to shareholders quoted Saint Augustine, the Gospel of Matthew, and a speech from Richard Nixon to staff on the day of his resignation in 1974.
His unorthodox style, however, doesn't appear to be getting in the way of results. On Monday, Palantir raised its forward guidance, projecting revenue to grow 36% to between $3.89 billion and $3.902 billion in 2025.
High expectations, however, are already baked into the stock price. Palantir shares currently trade at roughly 200 times its projected earnings over the next 12 months, according to estimates from S&P Capital IQ, compared with a forward P/E ratio of just over 20 for the S&P 500. That helps explain why the stock was down about 13% as of midday Tuesday, but shares are still up over 40% this year compared with the S&P's 4% decline.
Poised for the era of AI and DOGE
Mariana Pérez Mora, a VP of equity research in aerospace and defense at Bank of America, has called Palantir an 'overnight AI success 20 years in the making.' Karp echoed a similar message on Monday, citing a 'massive cultural shift in the U.S.' amid corporate America's embrace of the company's offerings. U.S. commercial revenue hit $255 million, soaring 71% compared with the same quarter last year and up 19% from the final quarter of 2024.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Is Palantir the Next Tesla?
Key Points Tesla is a popular stock among individual investors. Palantir also doesn't have much institutional ownership. Low institutional ownership can cause a stock to challenge traditional stock market practices. 10 stocks we like better than Palantir Technologies › Palantir's (NASDAQ: PLTR) impressive rise over the past few years has been nothing short of incredible. Still, there have also been questions surrounding Palantir's ability to deliver on the high expectations baked into the stock price. There has been no shortage of analysts calling for Palantir's fall (myself included) due to extreme valuation. This reminds me of another stock whose valuation metrics do not make a lot of sense: Tesla (NASDAQ: TSLA). However, Tesla has continued to defy traditional valuation metrics and has stayed at an elevated stock price for some time. Could Palantir fall into this same realm? Or is it so inflated that a crash is coming? Tesla and Palantir's rise look similar Tesla stock's primary rise started in 2020, increasing from about $24 per share all the way to around today's $340 per share. It returned over 1,100% over that time frame, resulting in a rise that few stocks have ever matched. Palantir's rise has similarly been rapid and impressive. Its stock rose from around $16 to $185 at the time of this writing, resulting in about 1,000% gains. Both companies delivered impressive performance in a very short amount of time, despite not increasing their revenue by 10 times (or more) over that time frame. As a result, most investors assume that they've grown too fast and are ripe for a pullback. But this analysis excludes a significant aspect of the investment thesis. Palantir and Tesla have low institutional ownership One of the reasons why Tesla's stock did so well over that time frame is that individual investors owned it. Individual investors don't have the same mindset as institutions. Various funds and other money managers are likely more devoted to traditional valuation metrics. If their discounted cash flow (DCF) models don't work out, then they avoid the stock entirely. However, companies like Tesla and Palantir break the mold of what traditional finance teaches, which can invalidate the assumptions that go into these models. Individual investors are far more likely to take a long-term view and note that Tesla's technology and vision could allow it to deliver massive growth over the long term. This illustrates a huge difference in approaches: Institutional investors utilize trailing metrics to predict the future, while individual investors look at the world and see where it could go. This difference has allowed stocks like Tesla and Palantir to thrive, leading to massive market outperformance as individual investors are less concerned with traditional valuation measures. Whether you think that's a correct approach to these two stocks or not is irrelevant; it's what's going on. Luckily, we have access to a metric that measures the percentage of shares outstanding that institutions own. For Tesla, about 49% of shares outstanding are institutionally owned. Compared to other tech giants, this is rather low. For comparison, Alphabet and Meta Platforms each have about 78% of shares outstanding owned by institutional investors. That's quite the difference and shows how much individuals, rather than large institutions, own Tesla. Palantir is in the same territory as Tesla, with about 53% of shares owned by institutions. Compared to the two closest companies in market cap to Palantir, Costco and ExxonMobil, these two have 69% and 67% of shares owned by institutional investors, respectively. Because Palantir has a similarly small amount of shares owned by institutional investors as Tesla, the stock will likely continue to perform in a manner that some may consider irrational. The decision to invest in Palantir is up to you, but investors need to be aware that after Tesla's massive run, the stock became incredibly volatile. Palantir could be approaching that point, but we'll find out in the coming years. Should you buy stock in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Keithen Drury has positions in Alphabet, Meta Platforms, and Tesla. The Motley Fool has positions in and recommends Alphabet, Costco Wholesale, Meta Platforms, Palantir Technologies, and Tesla. The Motley Fool has a disclosure policy. Is Palantir the Next Tesla? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
Seeking Up to 11% Dividend Yield? Analysts Pick 2 Dividend Stocks to Buy
The stock markets hit a low in April, and have since shown a tremendous rebound – but can it last? That's the question investors are wrestling with now, and it seems they are getting some pointers from Barry Bannister, chief equity strategist at Stifel. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bannister believes that the stock rebound – fueled by the AI boom, and the rush of capital spending as companies moved to get ahead of tariffs during the first half of the year – is simply not sustainable, noting that the S&P 500 is trading at a historically high valuation. 'Valuation doesn't matter until it does,' Bannister says, and adds that he can see the S&P 500 index falling as low as 5,500, for a drop of nearly 15%. Despite this downbeat outlook, Bannister is not recommending that investors get out of the market. He's recommending, instead, that investors make defensive moves to seek protection from a turndown. That outlook will naturally push investors' attention toward high-yield dividend stocks. These represent the classic defensive play, and for good reason. Dividends offer investors a steady income stream, and high-yield dividends guarantee a sound return well above the rate of inflation. Against this backdrop, we've opened up the TipRanks database to take a look at two dividend stocks that the analysts are picking out as Buys. These are dividend stocks offering yields as high as 11%, a solid return by any standard. Let's give them a closer look. Ellington Financial (EFC) The first stock we'll look at here, Ellington Financial, is a REIT, a real estate investment trust. These companies operate through strategic investments, mainly in real properties, mortgages, and mortgage-related assets, in both the residential and commercial spheres. Ellington's particular strategy involves building a diverse investment portfolio, made up of both residential and commercial mortgage loans, along with residential and commercial mortgage-backed securities, as well as other assets, including consumer loans, collateralized loan obligations, and various mortgage-related and non-mortgage-related securities and derivatives. Ellington's main goal in building this portfolio is to generate returns for its stockholders – in the company's words, 'attractive risk-adjusted total returns.' Ellington's strategy is opportunistic, targeting remunerative investments, but the company takes a defensive posture as well, investing across a wide range of sectors to capitalize on disparate strengths in its portfolio and making risk management a key part of its activities. As of June 30 this year, Ellington Financial had a total of $16.1 billion in assets under management. This portfolio is managed by an experienced team – the company's portfolio managers average 30 years of industry experience. These features of Ellington's business, its focus on shareholder returns and the long experience of its management team, have helped the company to cement a reputation as a high-quality dividend payer. The company's dividend features a high yield, as well as a monthly payment schedule. The last declaration, made on August 7 for a September 30 payment, was for 13 cents per common share. That dividend annualizes to $1.56 per share and gives a powerful forward yield of 11.5%. In its 2Q25 financial report, Ellington listed its quarterly adjusted distributable earnings as $45 million, or 47 cents per share. This was more than enough to fully cover the dividend, which currently comes to 39 cents per quarter. Covering this stock for Piper Sandler, following the Q2 print, analyst Crispin Love laid out a clear case for investors to go long on EFC: 'Ellington posted a beat this quarter with strength in both its credit and Longbridge strategies. In April around the market volatility, Ellington saw opportunities to deploy capital in its core credit strategies and also saw attractive opportunities in securities. Following the volatility, EFC was able to complete six securitizations in the quarter, which is a record for the company. The company also experienced success from its loan originator platforms, and we would not be surprised to see more partnerships and equity stakes over the intermediate term. Specifically, if there is GSE reform it could limit Fannie and Freddie's footprint and provide opportunities for Ellington to grow further in the non-QM space which is an area of expertise. Management was positive on the forward earnings trajectory and continued coverage of the $0.39 dividend.' These comments back up Love's Overweight (i.e., Buy) rating, and his $14.50 price target implies a gain of 5.5% in the next 12 months. But with the dividend yield included the upside can reach 17%. (To watch Love's track record, click here) There are 7 recent analyst reviews on record for Ellington, and the 5-to-2 split, favoring Buys over Holds, supports a Moderate Buy consensus rating. The Street's average target of $14.25 is the same as Love's. (See EFC stock forecast) LPG) Our world runs on energy, and the next company on our list here, Dorian LPG, is a leading carrier of that energy. Dorian is an owner/operator of very large gas carriers, VLGC vessels, which are the largest ocean-going carriers of liquefied petroleum gas, an important fuel in the world economy. The core of Dorian's business is its fleet of ships. The company maintains a modern fleet of VLGCs, with the oldest ship dating back to 2007. Most of the company's vessels were launched much more recently, in 2015, and the newest vessels in the fleet were launched in 2023. The vessels have an average age of 8 years, and their aggregate carrying capacity is some 2.1 million cubic meters of LPG. Dorian owns 21 of its ships, and operates the others on charter agreements. Most of the ships in Dorian's fleet are flagged in the Bahamas, although several are flagged in Liberia, Madeira, or Panama. The company is headquartered in Connecticut and has offices in Copenhagen and Athens. The international office footprint, and varying flags, are also common on the world's oceangoing cargo carriers. Dorian finished its last quarter, fiscal 1Q26 (June quarter), with just over $278 million in cash and liquid assets. The company pays an irregular dividend, meaning it has no obligation to pay out, or to maintain dividend payments at any level; while this poses risks for investors, it also allows the company to adjust the dividend to keep them affordable. That said, Dorian has been paying out dividends since 2021, and has not missed a quarterly payment in that time. The most recent dividend, declared on August 1 for payment on the 27th, set the rate at 60 cents per share. This dividend annualizes to $2.40 per common share, and gives a forward yield of 8%. On the financial side, Dorian generated $84.2 million in total revenues during its fiscal first quarter, a total that was down 26% year-over-year and fell shy of analyst expectations by $2.3 million. Additionally, adj. EPS of $0.27 missed the Street's forecast by $0.34. Despite the weak report, Jefferies analyst Omar Nokta remains bullish on the stock, writing: 'Dorian reported softer than expected fiscal 1Q26 results mainly due to higher G&A and higher drydocking costs, and also slightly lower than expected revenues… We view this earnings miss as a one-off… VLGC spot rates have strengthened materially and are at 2025 highs, setting up a very strong upcoming result next quarter and potentially a higher dividend… The company remains dedicated to returning capital to shareholders, and its shares trade at a discount to our NAV valuation of $33.80/sh… Dorian is our top pick in the LPG space, and we remain constructive on the name.' The 5-star analyst rates LPG shares as a Buy, and gives them a price target of $35, pointing toward a one-year gain of 16.5%. (To watch Nokta's track record, click here) There are only 2 recent analyst reviews on file for Dorian, but both are positive, giving the stock its Moderate Buy consensus rating. The shares are priced at $30.06, and the $33 average price target implies a 10% upside potential on the one-year horizon. (See LPG stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
